
VBIO
Healthcare · Biotechnology · $1.1M market cap
$0.5293+0.02 (+4.1%)Nov 13, 4:27 PM EST
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2023
EPS trend, 90 days to now
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 13, 2026 | Time not confirmed | — | — | — |
| Aug 14, 2026 | Time not confirmed | — | -2.17 | — |
| May 15, 2026 | Time not confirmed | — | -53.77 | — |
| Nov 17, 2025 | Time not confirmed | — | -49.14 | — |
| Aug 15, 2025 | Time not confirmed | — | -54.78 | — |
| May 15, 2025 | Time not confirmed | — | -2.52 | — |
| Mar 24, 2025 | Time not confirmed | — | -66.30 | — |
| Nov 15, 2024 | Time not confirmed | — | -98.23 | — |
| Aug 15, 2024 | Time not confirmed | — | -134.19 | — |
| May 16, 2024 | Time not confirmed | — | -428.84 | — |
| Mar 26, 2024 | Time not confirmed | — | -650.22 | — |
| Nov 14, 2023 | After the close | -119.00 | -25.16 | +78.9% |
| Aug 14, 2023 | After the close | -136.00 | -119.00 | +12.5% |
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition,…
| May 16, 2023 |
| Time not confirmed |
| -187.00 |
| -187.00 |
| 0.0% |
| Mar 31, 2023 | Before the open | -527.00 | -391.00 | +25.8% |
| Nov 14, 2022 | Before the open | -544.00 | -459.00 | +15.6% |
| Aug 15, 2022 | After the close | -408.00 | -544.00 | -33.3% |
| Jun 1, 2022 | Time not confirmed | — | -9799.04 | — |